Supporting Statement for
Exceptions or Alternatives to Labeling Requirements for Products Held by the Strategic National Stockpile; interim final rule
OMB # 0910-XXXX
The Food and Drug Administration (FDA) is requesting Office of Management and Budget (OMB) approval of the information collection provisions listed below (Tab A):
21 CFR Section |
Category |
Description |
201.26(b)(1)(i) |
Reporting |
A Strategic National Stockpile (SNS) official or any entity that manufactures (including labeling, packing, relabeling, or repackaging), distributes, or stores a human drug product that is or will be included in the SNS may submit, with written concurrence from a SNS official, a written request for an exception or alternative to certain provisions to the appropriate Center Director. |
610.68(b)(1)(i) |
Reporting |
A SNS official or any entity that manufactures (including labeling, packing, relabeling, or repackaging), distributes, or stores a biological product that is or will be included in the SNS may submit, with written concurrence from a SNS official, a written request for an exception or alternative to certain provisions to the appropriate Center Director. |
801.128(b)(1)(i) |
Reporting |
A SNS official or any entity that manufactures (including labeling, packing, relabeling, or repackaging), distributes, or stores a device that is or will be included in the SNS may submit, with written concurrence from a SNS official, a written request for an exception or alternative to certain provisions to the appropriate Center Director. |
809.11(b)(1)(i) |
Reporting |
A SNS official or any entity that manufactures (including labeling, packing, relabeling, or repackaging), distributes, or stores an in vitro diagnostic product for human use that is or will be included in the SNS may submit, with written concurrence from a SNS official, a written request for an exception or alternative to certain provisions to the appropriate Center Director. |
Under the Public Health Security and Bioterrorism Preparedness and Response Act and other relevant statutes, the Department of Health and Human Services (HHS) stockpiles medical products that are essential to the security of the nation (see Public Law 107-188, Title I, section 121 (June 12, 2002)). As established in section 3 of the Project BioShield Act of 2004 (section 319F-2 of the Public Health Service Act (the PHS Act) (42 U.S.C. 247d-6b)), this collection of medical products for use during national health emergencies, known as the Strategic National Stockpile (SNS), is to “provide for the emergency health security of the United States, including the emergency health security of children and other vulnerable populations, in the event of a bioterrorist attack or other public health emergency.”
It may be appropriate for certain medical products that are or will be held in the SNS to be labeled in a manner that would not comply with certain FDA labeling regulations, given their anticipated circumstances of use in an emergency. However, noncompliance with these labeling requirements could have rendered such products misbranded under section 502 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 352).
The interim final rule would allow the appropriate FDA Center Director to grant an exception or alternative to certain FDA labeling requirements if compliance with the requirements could adversely affect the safety, effectiveness, or availability of products that are or would be in the SNS. An exception or alternative granted under this rule may include conditions or safeguards so that the labeling for such products includes appropriate information necessary for the safe and effective use of the product given the product’s anticipated circumstances of use. This rule would facilitate the safety, effectiveness, and availability of appropriate medical countermeasures and in the event of a public health emergency.
If the request is granted, the manufacturer may need to report to FDA any resulting changes to the new drug application (NDA), biologics license application (BLA), premarket approval application (PMA), or premarket notification (510(k)) in effect, if any. The submission and grant of a request for an exception or alternative to the labeling requirements specified in this rule may be used to satisfy certain reporting obligations relating to changes to product applications under § 314.70 (21 CFR 314.70) (human drugs), § 601.12 (21 CFR 601.12) (biological drugs), § 814.39 (21 CFR 814.39) (medical devices subject to premarket approval), or § 807.81 (21 CFR 807.81) (medical devices subject to premarket notification submission (510(k) clearance) requirements).
The information collection provisions in §§ 314.70, 601.12, 807.81 and 814.39 have been approved under OMB control numbers 0910-0001 (expires May 31, 2008), 0910-0338 (expires September 30, 2008), 0910-0120 (expires August 31, 2010), and 0910-0231 (expires November 30, 2010), respectively.
One of FDA’s continuing objectives is to improve the speed and quality of its review and approval programs. FDA utilizes electronic information system technologies where applicable. FDA believes the increased use of computer-assisted information technology, such as regulatory submissions in electronic format, enhances the timeliness, effectiveness, and efficiency of the review process and reduces burdensome, nonessential hard-copy handling and storage. FDA is not aware of any other improved technology to reduce the burden.
FDA is the only agency that requires the request for an exceptions or alternatives to certain labeling requirements applicable to human drugs, biological products, and medical devices that are or would be included in the SNS. No other component of FDA or other government agencies requires similar information or data to be submitted. This information is not available from any other source.
Although FDA must apply the statutory and regulatory requirements equally to all enterprises, FDA does provide special help to small businesses. The Center for Biologics Evaluation and Research (CBER), Office of Communications, Training, and Manufacturers Assistance, the Center for Drug Evaluation and Research, Office of Training and Communication, and the Center for Devices and Radiological Health, Division of Small Manufacturers, International and Consumer Assistance provide assistance to small businesses subject to FDA’s regulatory requirements.
Less frequent collection of this and other information would not provide the information that FDA needs to facilitate the safety, effectiveness, and availability of appropriate medical countermeasures in the event of a public health emergency.
An entity may be required to submit to FDA proprietary trade secret or other confidential information when submitting a request for an exception or alternative to the labeling requirements. FDA has instituted security measures to protect confidential information received and will, to the extent permitted by law, protect the information.
In accordance with 3507(j) of the PRA (44 U.S.C. 3507(j) and 5 CFR 1320.13), FDA is publishing in the Federal Register an emergency processing notice requesting public comment on the information collection provisions in the interim final rule.
No payment or gift was provided to respondents.
The confidentiality of information received by FDA would be consistent with the Freedom of Information Act and FDA’s regulations under 21 CFR Part 20, 21 CFR 312.130, 314.430, 601.50, 601.51, 807.95, 809.4, 812.38, and 814.122. Proprietary or trade secret information is deleted from any information released by FDA under the Freedom of Information Act and FDA regulations.
Questions of a sensitive nature are not applicable to this information collection.
The total annual estimated burden imposed by this collection of information is 720 hours annually.
Table 1. – Estimated Annual Reporting Burden |
|||||
21 CFR Section |
No. of Respondents |
Annual Frequency per Response |
Total Annual Responses |
Hours per Response |
Total Hours |
201.26(b)(1)(i) |
18 |
1 |
18 |
24 |
432 |
610.68(b)(1)(i) |
10 |
1 |
10 |
24 |
240 |
801.128(b)(1)(i) and 809.11(b)(1)(i) |
2 |
1 |
2 |
24 |
48 |
Total |
720 |
||||
Respondents to this collection of information are entities that manufacture (including labeling, packing, relabeling, or repackaging), distribute or store affected products.
Although FDA cannot predict the number of future requests, based on limited information within FDA, we estimate that approximately 30 respondents would request annually one exception or alternative to labeling provisions to avoid misbranding of their products in the SNS. The estimate of one request per respondent is based on the anticipated occasional occurrence of a product being misbranded while in the SNS. We are estimating that each respondent would spend from 8 to 24 hours preparing each request. The hours per response are based on estimated time that it takes to prepare a supplement to an application, which may be considered similar to a request for an exception or alternative.
The information collection provisions in §§ 314.70, 601.12, 807.81 and 814.39 have been approved under OMB control numbers 0910-0001 (expires May 31, 2008), 0910-0338 (expires September 30, 2008), 0910-0120 (expires August 31, 2010), and 0910-0231 (expires November 30, 2010), respectively.
Cost to Respondents
The estimated annual cost to respondents is $34,020.
Activity |
No. of Hours |
Cost per Hour |
Total Cost |
Reporting |
720 |
$47.25 |
$34,020 |
The cost estimate is based on a regulatory affairs specialist, at a pay rate of $47.25/hour, who would be responsible for preparing a submission. The estimated average hourly pay rate includes benefits but no overhead costs.
There are no other costs associated with this collection.
The estimated annual cost to FDA is $36,600.
Activity |
Number of Reviews |
Average Hours per Review |
Average Cost per Hour |
Total Cost |
Review & Process |
30 |
20 |
$61 |
$36,600 |
This estimate is based on FDA regulatory review staff with an average pay of $61/hour spending an estimated average of 20 hours to review and process the submissions to FDA. This salary estimate includes benefits but no overhead costs.
This interim final rule contains a new collection of information that would allow the appropriate FDA Center Director to grant an exception or alternative to certain FDA labeling requirements if compliance with the requirements could adversely affect the safety, effectiveness, or availability of products that are or would be in the SNS. An exception or alternative granted under this rule may include conditions or safeguards so that the labeling for such products includes appropriate information necessary for the safe and effective use of the product given the product’s anticipated circumstances of use. This rule would facilitate the safety, effectiveness, and availability of appropriate medical countermeasures and in the event of a public health emergency.
There are no tabulated results to publish for this information collection.
FDA is not seeking approval to exempt the display of the expiration date of the OMB approval.
Not applicable.
| File Type | application/msword |
| File Title | OMB INFORMATION COLLECTION |
| Author | CBER |
| Last Modified By | Jonna Capezzuto |
| File Modified | 2007-11-08 |
| File Created | 2007-11-08 |